New eye drops aim to soothe dry, red eyes
NCT ID NCT07007702
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new preservative-free eye drop (Thealoz Total) in 30 adults with chronic dry eye and eye redness. Participants used the drops daily for 12 weeks. Researchers measured changes in redness and how satisfied patients felt. The goal was to see if the drops improve comfort and reduce inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trehalose, sodium hyaluronate, and N-Acetyl Aspartyl Glutamic Acid (NAAGA) in preservative-free eye drops
What this could lead to
If successful, this could offer a new option for people with chronic dry eye to reduce redness and feel more comfortable.
What could go wrong
This is a small, early study with only 30 people and no comparison group, so results may not apply to everyone. The drops are meant to ease symptoms, not cure dry eye.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitätsklinik für Klinische Pharmakologie, Allgemeines Krankenhaus Wien
Vienna, Austria